Michael Sacerdote

MacroGenics: Big Dreams, Good Molecules

Although the IPO market has become relatively frothy, the opportunity remains for biotech investors who carefully vet the offerings to buy great science on the cheap. This week, MacroGenics (NASDAQ:MGNX) brings solid drug prospects, albeit in a highly competitive opportunity space. Using conservative risk discounting, I estimate the true value of the company to be $568-$628 million, or $21.85-$24.15 per share.

Underlying technology

While MacroGenics is like many other young biotech companies in that one prospect dominates its valuation, MacroGenics also owns bona fide development platforms for further drug discovery beyond its lead compound. MacroGenics has two core scientific platforms for drug discovery: Fc-optimized antibodies and dual affinity re-targeted antibody-related molecules (DARTs).

(click to enlarge)

Figure 1. Pipeline....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details